Eribulin Not Superior to Capecitabine for Previously Treated Breast Cancer
the Cancer Therapy Advisor take:
According to a new study published in the Journal of Clinical Oncology, researchers have found that eribulin mesylate is not superior to capecitabine for the treatment of patients with locally advanced or metastatic breast cancer who were previously treated with an anthracycline and a taxane.
In this open label, phase 3 study, researchers sought to compare the efficacy of eribulin mesylate versus capecitabine for advanced/metastatic breast cancer.
Researchers enrolled 1,102 women with metastatic breast cancer who had previously received anthracycline- and taxane-based therapy and randomly assigned them to receive either eribulin or capecitabine as their first-, second-, or third-line chemotherapy for advanced disease.
Results showed median overall survival times of 15.9 months and 14.5 months for eribulin and capecitabine, respectively (HR = 0.88; 95% CI: 0.77 - 1.00; P = 0.056). Median progression-free survival times were 4.1 months for the eribulin arm and 4.2 months for the capecitabine arm (HR = 1.08; 95% CI: 0.93 - 1.25; P = 0.30).
In addition, the eribulin group had an 11.0% objective response rate compared with 11.5% in the capecitabine group. Researchers also found that both treatments had manageable safety profiles.
Eribulin mesylate is not superior to capecitabine for the treatment of locally advanced or metastatic breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer